INT11905

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 1.00
First Reported 1991
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 2.36
Pain Relevance 2.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (EPO) extracellular space (EPO) aging (EPO)
extracellular region (EPO)
Anatomy Link Frequency
liver 1
brain 1
kidney 1
EPO (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 3 100.00 Very High Very High Very High
cINOD 1 99.16 Very High Very High Very High
Pain 15 96.88 Very High Very High Very High
ischemia 7 84.32 Quite High
Versed 1 84.16 Quite High
Spinal cord 1 83.12 Quite High
cva 2 80.16 Quite High
anesthesia 8 75.00 Quite High
visual analogue scale 1 73.84 Quite High
gABA 5 68.80 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 7 98.92 Very High Very High Very High
Fungal Infection 1 96.24 Very High Very High Very High
Pain 10 93.08 High High
Renal Failure 2 92.00 High High
Uremia 1 90.80 High High
Injury 5 86.32 High High
Cv Unclassified Under Development 4 84.32 Quite High
Disorders Of Creatine Metabolism 5 83.68 Quite High
Brain Injury 28 83.52 Quite High
Frailty 2 83.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because removal of the liver and kidney had no effect on EPO elimination, the metabolic degradation of EPO occurs in a tissue compartment that is yet to be defined.
Protein_catabolism (degradation) of EPO in kidney
1) Confidence 1.00 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8968342 Disease Relevance 0 Pain Relevance 0.24
[Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis.
Protein_catabolism (tolerance) of erythropoietin associated with tolerance
2) Confidence 0.89 Published 1992 Journal Nephrologie Section Title Doc Link 1608502 Disease Relevance 0.12 Pain Relevance 0.21
Special mention is made of epoetin (recombinant human erythropoietin).
Protein_catabolism (made) of erythropoietin
3) Confidence 0.89 Published 1991 Journal Clin Pharmacokinet Section Abstract Doc Link 2036748 Disease Relevance 0.87 Pain Relevance 0.10
Although the discomfort of rHuEpo beta is graded as very mild by most adult patients the use of Emla is associated with a significant reduction in discomfort, which may be of benefit to paediatric patients.
Protein_catabolism (graded) of rHuEpo
4) Confidence 0.86 Published 1994 Journal Nephrol. Dial. Transplant. Section Abstract Doc Link 7816294 Disease Relevance 0.65 Pain Relevance 0.90
Interestingly, EPO and its receptor are both expressed by the nervous system, and systemically administered rHuEPO can reach sites within the brain.
Protein_catabolism (its) of EPO in brain
5) Confidence 0.41 Published 2006 Journal Crit Care Section Body Doc Link PMC1794449 Disease Relevance 0.72 Pain Relevance 0.30
Because removal of the liver and kidney had no effect on EPO elimination, the metabolic degradation of EPO occurs in a tissue compartment that is yet to be defined.
Protein_catabolism (degradation) of EPO in liver
6) Confidence 0.34 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8968342 Disease Relevance 0 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox